Nikhil I. Khushalani, MD, associate member and vice chair of cutaneous oncology at Moffitt Cancer Center, provides insight on how predictive and prognostic biomarkers can influence immuno-oncology treatment, but acknowledges that further research is still needed to determine the best course of therapy.